Latest Intelligence on Pharmaceuticals and Healthcare in Middle East and Africa

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Biologics: a growing but threatened market

Published By Datamonitor
30 Jun 2006
Expert View
Expert View

Diverse challenges await generics industry

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.

Published By Datamonitor
07 Jul 2006
ResearchWire
ResearchWire

Pipeline management: Mid Pharma big on in-licensing

Published By Datamonitor
14 Jul 2006
ResearchWire
ResearchWire

Hepatitis C: protease inhibitors to drive market expansion

Published By Datamonitor
21 Jul 2006
ResearchWire
ResearchWire

Antiarrhythmics market: new product launches to reinvigorate growth

Published By Datamonitor
21 Jul 2006
ResearchWire
ResearchWire

Big Pharma: rising R&D spend

Published By Datamonitor
28 Jul 2006
Expert View
Expert View

Directed molecular evolution: lifecycle management for biologics

Although biologics have an extremely attractive growth rate profile compared to small molecules, the rapid market expansion expected to occur between 2005 and 2010 will not continue at the same rate, due in part to the emergence of biosimilars. Thus, biologics manufacturers need to look at optimizing the lifecycle of their products through directed molecular evolution.

Published By Datamonitor
02 Aug 2006
Expert View
Expert View

Generics set to take precedence in schizophrenia market

It is estimated that 1% of the entire world's population suffers from schizophrenia. In an effort to treat this crippling disease, the global schizophrenia market will continue to grow in value until 2010, when revenues will reach $3.8 billion. However, thereafter, despite the commercial launch of numerous new drugs, the market's value will decline as generics come into the prescribing equation.

Published By Datamonitor
16 Aug 2006
ResearchWire
ResearchWire

Acute stroke: AstraZeneca drug candidate offers blockbuster potential

Published By Datamonitor
31 Aug 2006
ResearchWire
ResearchWire

Neuropathic pain: opportunities await despite generic threat

Published By Datamonitor
29 Sep 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.